Formycon AG has entered into an exclusive license agreement with Lotus Pharmaceutical for the development and commercialization of its Keytruda® biosimilar candidate, FYB206, aimed at improving patient access to oncology treatments in the Asia-Pacific region.

Information on the target

Formycon AG (FSE: FYB) is a prominent independent developer specializing in high-quality biosimilars and follow-on products for biopharmaceutical medicines. The company is dedicated to advancing therapies in critical areas such as ophthalmology, immunology, and immuno-oncology. Formycon manages the entire value chain, from technical development through clinical trials to regulatory approval, ensuring that patients have access to effective and affordable treatments.

Recently, Formycon has entered into an exclusive license agreement with Lotus Pharmaceutical for its Keytruda® biosimilar candidate, FYB206. This partnership aims to enhance patient access to this vital oncology therapeutic across major parts of the Asia-Pacific region, leveraging both companies' strengths in development and commercialization.

Industry overview in the target’s specific country

The Asia-Pacific region is witnessing significant growth in the biopharmaceutical sector, driven by increasing healthcare demands and a rising prevalence of chronic diseases. The market for biosimilars, in particular, is expandin